2017. Burden and profile of somatic mutation in duodenal adenomas from patients with familial adenomatous-and MUTYH-associated polyposis. Statement of translational relevance: Surveillance duodenoscopy is undertaken in patients with familial adenomatous polyposis (FAP) or MUTYH-associated polyposis (MAP) to reduce the risk of duodenal cancer. Current guidelines in the USA and Europe recommend that the screening interval and decisions on interventions are based upon Spigelman staging of duodenal polyposis. In this study we demonstrate a greater mutational burden in MAP than FAP duodenal adenomas despite lower Spigelman stage duodenal polyposis in the MAP patients studied. These findings suggest that the risk of progression to cancer in the context of early stage duodenal polyposis could be higher in MAP than FAP patients and challenge the assumption that the same surveillance protocols should be applied in MAP and FAP. Abstract Purpose: Duodenal polyposis and cancer are important causes of morbidity and mortality in familial adenomatous polyposis (FAP) and MUTYHassociated polyposis (MAP). This study aimed to comprehensively characterize somatic genetic changes in FAP and MAP duodenal adenomas to better understand duodenal tumorigenesis in these disorders. Experimental Design: Sixty-nine adenomas were biopsied during endoscopy in 16 FAP and 10 MAP patients with duodenal polyposis. Ten FAP and 10 MAP adenomas and matched blood DNA samples were exome sequenced, Research. on August 11, 2017.
Introduction
Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP) are inherited disorders characterized by colorectal polyposis and cancer. They are also associated with extra-colonic manifestations including polyposis and cancer in the upper gastrointestinal tract, most notably duodenal disease that has become an important cause of morbidity and mortality as the management of colorectal disease has improved (1) . A recent study of FAP estimated the lifetime risk of duodenal polyposis to be 88% and of cancer to be 18% (2) . In a multicenter retrospective study of MAP, duodenal polyps were noted in 26 of 150 (17%) patients undergoing duodenoscopy and the lifetime risk of duodenal cancer was estimated at 4% (3) . A more recent study in two specialist centers identified duodenal adenomas in 31 of 92 (34%) MAP patients undergoing endoscopy at a median age of 50 years (4) .
In patients with FAP or MAP regular endoscopic surveillance of the duodenum has been advocated from the age of 25-30 years (1). Spigelman staging based upon the number, size, dysplasia and presence of villous histology of adenomas was developed to better define the severity of duodenal disease in FAP (5) and is recommended to guide the frequency of surveillance, stratify cancer risk and inform decisions about surgical intervention (6) . Duodenal disease in FAP appears to progress slowly through Spigelman stages (0-IV) with an associated increase in cancer risk (7) . The natural history of duodenal polyposis in MAP is not well defined but there are reports of duodenal cancer Research.
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Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432. CCR-17-1269 occurring in the context of minimal background polyposis (3, 8) . More evidence is required to support or refute current recommendations to apply the same Spigelman stage-based surveillance and intervention for MAP as FAP (1, 6) .
Rapid recurrence of duodenal adenomas has been reported following endoscopic polypectomy in patients with FAP (9, 10) . Surgical treatments including ampullectomy, duodenectomy and pancreatico-duodenectomy appear effective for cancer prevention but are associated with significant procedure-associated risks (7, 11) . Medical treatment using the cyclooxygenase (COX) inhibitors sulindac and celecoxib has proven less effective in the duodenum than the colorectum (12) (13) (14) (15) but a recent trail of combined COX and epidermal growth factor receptor inhibition with sulindac and erlotinib demonstrated promising short-term effects on duodenal polyp burden (16). The efficacy of medical and surgical treatment or prevention of duodenal disease in MAP remains unknown.
In colorectal tumorigenesis, the nature and positions of APC mutations appear to determine a critical level of over-activation of β-catenin signaling that leads to a failure in cell growth control without induction of apoptosis (17), a scenario described by the "just right" hypothesis (18). The situation in FAPassociated upper gastrointestinal tumors appears to be subtly different as somatic APC mutations cluster in a more 3' region (19) . Severe upper intestinal polyposis is also associated with a more 3' location of inherited APC mutations (19).
Research.
Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432. CCR-17-1269 Recently, a comprehensive survey of the mutational landscape of colorectal adenomas from patients with FAP and MAP was made using exome sequencing (20) . This confirmed the importance of somatic APC and KRAS mutations as drivers of early colorectal tumorigenesis in both disease settings.
It also identified frequent somatic mutations of WTX (also known as FAM123B and AMER1) as had been reported previously in sporadic colorectal cancer (21) and that, like APC mutations, may act through deregulation of β-catenin turnover. Although comprehensive molecular genetic studies of duodenal adenomas or carcinomas in patients with FAP have not been reported, targeted sequencing has confirmed a role for APC and revealed oncogenic mutations of KRAS in 9-30% of FAP duodenal adenomas (22-25).
Comparable studies of MAP-associated duodenal tumors have not been reported.
In this study we applied whole exome and targeted Sanger sequencing and array comparative genomic hybridization (aCGH) to characterize somatic genetic variation associated with the development of duodenal adenomas in patients with FAP and MAP.
Materials and Methods

Patients and Samples
Ethical approval was granted by the UK NHS Research Ethics Committee system (reference 10/MRE093). All patients provided written informed For the latter, the percentage of epithelial adenoma nuclei was determined in relation to the total number of nuclei comprising adenoma, non-neoplastic crypts, stroma / lamina propria / muscularis mucosae / submucosa, lymphoid and inflammatory cells. The remainder of each biopsy was snap frozen with liquid nitrogen and stored at -80°C until DNA was extracted using the phenol/chloroform method. A potential limitation in sample characterization was that we could not confirm whether sections used for histopathology were representative of the rest of each biopsy.
Whole Exome Sequencing
Whole exome sequencing of adenoma and matched blood DNA was performed to a mean depth of coverage of 100x at the Beijing Genomics Institute, Hong Kong, using the SureSelect Human 50Mb capture kit (Agilent) and Illumina platforms. A potential limitation of the chosen depth of coverage is failure to detect somatic variants occurring at very low frequency due to tumor heterogeneity. Details of variant calling can be found in the suppl methods.
Validation of Somatic Mutations
Putative protein changing somatic mutations were validated by PCR and Sanger sequencing of original adenoma DNA samples. When the sequencing depth in a matched blood sample was 20x or less, PCR and Sanger sequencing was also performed on the blood DNA sample. Primers were purchased from Eurofins and PCR was completed as described in the supplementary methods.
Identification and Analysis of Recurrently Mutated Genes
Recurrently mutated genes were defined as those with ≥2 validated somatic protein changing mutations in the 20 duodenal adenoma exomes. Data for adenomas 37A1 and 37A4 and for adenomas 24A3 and 24A8 were merged as each of these pairs shared a significant proportion of confirmed somatic mutations indicating that they were not independent tumors. Mutations present in each of these pairs were counted only once. To determine which genes were significantly mutated, all validated variants were analyzed using MutSig v1.0 (http://www.broadinstitute.org/cancer/cga/mutsig). To adjust for multiple testing and reduce the false discovery rate, q values were calculated (32) . Genes with P< 0.05 (Fishers Exact test) and a Q<= 0.1 were reported as significantly mutated (see supplementary methods for details).
In order to gain insight into potential mechanisms of tumorigenesis, pathway enrichment analysis was undertaken on all 941 validated somatic mutations using ConsensusPathDB (33) (suppl methods).
Sanger Sequencing in Additional Adenomas
Sanger sequencing of 42 additional adenoma biopsies was used to extend data on somatic mutations in ERBB3, KRAS, PLCL1, PTCHD2 and WTX and of 49 additional adenomas for APC exon 15 (for details see supplementary methods).
Loss of Heterozygosity (LOH) Analysis
LOH analysis at the APC locus was performed on adenomas in which somatic APC mutations were not identified by sequencing (details in supplementary methods). A 50% or greater reduction in an allele relative to constitutional DNA was reported as allelic loss.
Identification and Confirmation of Somatic Copy Number Variants (CNVs)
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Published Data on Somatic APC Mutations in MAP and FAP Adenomas
We 
Results
Characterization of Patients and Adenomas
Biopsies of 72 apparently independent polyps were obtained (1 to 7 biopsied polyps per patient). Histology confirmed that 69 were adenomas including 42 from 16 patients with FAP and 27 from 10 patients with MAP (Table 1) . Two biopsies contained only normal mucosa and one only inflamed ampullary tissue. MAP patients were significantly older than those with FAP (mean 55.0 years versus 42.9 years, P = 0.006), but had significantly lower Spigelman stage disease (mode stage II versus IV, P = 0.031). Spigelman stage was also lower in MAP than FAP patients from whom adenomas were used for whole exome sequencing (stages II,II,II,II,III vs III,III,III,IV respectively). There was no significant difference in the size of biopsied adenomas from FAP and MAP patients (mean 6.93 mm, range 1-30 mm, SD 6.35 mm versus mean 8.12 mm, range 1.5-25 mm, SD 6.14 mm, P = 0.4255) or in the size of FAP and MAP adenomas used for whole exome sequencing (mean 11.1 mm, range 2-25 mm, SD 7.5 mm versus mean 11.7 mm, range 3-25 mm, SD 8.26 mm respectively, P = 0.867). All adenomas showed only low grade dysplasia and most had tubular morphology with 7/42 (17%) of FAP adenomas and 2/27
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Somatic Mutation Landscape in FAP and MAP Duodenal Adenomas
Whole exome sequencing of 20 duodenal adenomas, 10 from 4 patients with FAP and 10 from 5 patients with MAP, together with matched blood DNA identified 1449 putative protein altering somatic mutations. PCR and Sanger sequencing validated 941 of these (65%, Supplementary Table 1 and 2)
including 28 APC mutations that were identified initially by manual inspection of the exome data and 913 variants in other genes. Eighty three percent of the validated mutations were nonsynonymous (missense) changes, 13% were stopgains, 2% were splice site mutations, 1% were frameshifts and one was a stoploss. There were significantly more validated protein changing somatic mutations in MAP relative to FAP adenomas (mean 71.6, SD 53.56, range 8-167 vs mean 22.5, SD 13.25, range 1-44, P = 0.0115; t-test) (Suppl Figure 1 and Supplementary Table 1 ). This equated to a mean of 1. Figure 1 ).
We also tested for a correlation between adenoma size and the number of Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. somatic variants. A further 167 validated variants were not shared. MAP adenomas 24A3 and 24A8 also appeared distinct at endoscopy but shared the same somatic APC mutations and 60 other validated variants while 34 validated variants were not shared. The proportions of adenomatous nuclei also differed between adenomas in these pairs (Table 1) . Each pair was considered likely to have diverged from a single progenitor lesion and variants in each pair were counted only once in analyses to identify recurrently mutated genes.
Recurrently Mutated Genes
Sixty-two genes were mutated recurrently in the adenomas subject to whole exome sequencing ( Supplementary Table 3 ) but analysis with MutSig v1.0, which evaluates the number of mutations observed in the context of gene size and the background mutation rate, showed that only 15 were mutated significantly more often than expected ( Table 2 ). Of these, 12 were also mutated significantly in the COSMIC database of somatic mutations in cancer (http://cancer.sanger.ac.uk/cosmic) ( Table 2) . Truncating mutations were observed recurrently in APC, PIGA, TRPM1 and SYNE1 but only APC and PIGA were mutated significantly above the expected background rate. PIGA was not mutated significantly in COSMIC and therefore does not appear to be a driver gene in more extensively studied tumor types. (20) and is also among the most frequently mutated genes in non-hypermutated colorectal cancer (21). We therefore also sequenced WTX in 42 further duodenal adenomas.
Forty further APC mutations were identified by Sanger sequencing (Tables 1   and 4 ) and LOH analysis revealed somatic loss affecting 3 further APC alleles in which sequencing was normal. As aCGH detected no CNVs at the APC locus the LOH appeared to be copy neutral.
The somatic APC mutations and those reported in previous studies of FAP duodenal adenomas (see Supplementary Table 4 ) clustered 3' to the third (last) β-catenin binding 20 amino acid repeat. This non-random clustering was highly significant (P = 9.11x10 -10 by the method of Ye et al (35) ) and different to the clustering of somatic APC mutations in FAP-associated colorectal adenomas ( Supplementary Table 4 ) that occurs after the first and second 20 amino acid repeats (P <3.72x10 -16 and P <3.88x10 -29 Table 4 , P < 0.0001; Fisher's exact test).
In MAP duodenal adenomas where biallelic APC mutations were identified, significant clustering occurred between codons 1530 and 1576 (P = 1.25x10 -7 ) despite the presence of GAA sequences throughout the coding region that could be mutated to stop codons by G>T transversion with only one instance of E1554fsX5 observed (in the adenoma pair 37A1 and 37A4, Supplementary   Table 4 ).
We did not observe any somatic WTX mutations in 60 independent duodenal adenomas ( Table 3) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. test). Only 3/8 KRAS mutations in MAP duodenal adenomas were the c.34 G:C>T:A (G12C) mutation that has been considered as a potential biomarker of MAP in patients with multiple colorectal adenomas (36) . MAP patients whose adenomas harbored KRAS mutations appeared to have lower Spigelman stage polyposis than corresponding FAP patients (stages II,II,II,II,III in MAP vs II,IV,IV in FAP, Table 1 ).
Six somatic PTCHD2 mutations were identified in 60 independent adenomas, 3 by whole exome sequencing and 3 by sequencing of additional adenomas.
Five had CADD scores above 20 (i.e. corresponding to the top 1% of substitutions in terms of predicted deleterious effects). Adenomas 3A2 and 37A1 each contained two PTCHD2 mutations but one of those in 37A1 was unlikely to be of functional significance (Supplementary Table 5 ). Six independent PLCL1 mutations were also observed: 4 in whole exomes and 2 following targeted sequencing. The latter 2 did not cluster with the others (Supplementary Table 5 ). All but one of the PLCL1 mutations had CADD scores above 20. No further mutations of ERBB3 were identified by analysis of the 42 additional adenomas but the 2 mutations identified during exome sequencing had CADD scores of 28.4 and 30 and are very likely to impact function ( Supplementary Table 5 ).
Array CGH
Array CGH revealed 8 CNVs (5 losses and 3 gains) in 5 of 19 MAP duodenal adenomas ( Table 4) Fisher's exact test). All were confirmed by either quantitative PCR or by using a second array, the Illumina CytoSNP-850k v1.0. Several involved genes in the BMP/TGF-β signaling pathway: the deletion at 18q21.1 in adenoma 44A4 included SMAD4 and that at 9q22 included ENG, while the 15q11.1-15q21.1 gains in adenomas 23A3 and 23A4 included GREM1, a BMP antagonist.
Discussion
Duodenal polyposis and cancer present a major challenge in the clinical management of FAP and MAP, but remain understudied and poorly understood. This study is the first to characterize comprehensively the burden and pattern of somatic mutations in duodenal adenomas from patients with FAP or MAP. We found that MAP duodenal adenomas carried a significantly higher burden of somatic protein changing mutations, truncating mutations and CNVs than FAP duodenal adenomas even though MAP patients had lower Spigelman stage duodenal polyposis than FAP patients. The greater mutation burden in MAP adenomas appears to reflect defective base excision repair. Although longitudinal or prospective studies of duodenal polyposis in MAP have not been reported, case reports have highlighted the occurrence of duodenal cancer in MAP patients in the absence of advanced duodenal polyposis (3, 8) . These observations and our data suggest that current recommendations to manage MAP duodenal polyposis using Spigelman staging in the same way as for FAP (1,6) may not be appropriate. A low polyp count in a patient with MAP may be falsely reassuring and, in addition, we did not find a significant correlation between adenoma size and mutation burden. Mutation burdens in some small MAP adenomas were among the highest we observed. Large, prospective clinical studies could provide a better evidence base for duodenal surveillance recommendations and intervention in MAP.
Our data confirm the importance of APC and KRAS mutations as drivers of duodenal tumorigenesis in FAP and MAP but show that in contrast with the colorectum (20,21,37,38) WTX is not a significant driver gene in early duodenal tumorigenesis. Neither did we identify by exome sequencing any mutations in a number of known driver genes including NRAS, CTNNB1, FBXW7 and TP53 that were mutated recurrently in previous studies of sporadic or FAP-associated colorectal adenomas (37, 39) and that are also mutated in sporadic duodenal adenocarcinomas (40, 41) . They may be mutated later in duodenal tumorigenesis.
The somatic APC mutations we identified in FAP and MAP duodenal (1/296 mutations in the reports we identified, Supplementary Table 4 ), this mutation has been seen recurrently in colorectal adenomas from patients with attenuated FAP (43-45) where it appears to occur as a "third hit" further reducing the activity of the attenuated germline mutant allele. We did not find any evidence for third hits affecting APC in duodenal adenomas. Instead, this change and the others clustering after the 3 rd 20 AA repeat are likely to be selected for as second hits in duodenal tumorigenesis because they determine a specific level of β-catenin signaling that is lower than that selected for in colorectal tumorigenesis. A subtly different β-catenin signaling requirement in duodenal adenomas may also explain the absence of WTX mutations.
In addition to APC and KRAS, 10 of the 13 other genes that were mutated significantly upon whole exome sequencing of duodenal adenomas are also mutated significantly in the COSMIC database of somatic mutations in cancer (Table 2 ). These genes are likely to be drivers in FAP and MAP duodenal tumors as well as in other tumor types. Following whole exome sequencing we investigated the recurrently mutated genes PTCHD2, ERBB3 and PLCL1 in a set of 42 additional duodenal adenomas. We identified further mutations in PTCHD2 (N = 3) and PLCL1 (N = 2), supporting a role for these genes as Table 1 . Details of patients and adenomas studied. Adenomas with IDs in gray boxes were subject to whole exome sequencing. TA = tubular adenoma, TVA = tubulovillous adenoma, VA = villous adenoma, LGD = low grade dysplasia. Non-independent adenomas are shown in bold. Total numbers of adenomas were counted following chromoendoscopy. Table 2 . Significantly mutated genes identified by MutSig analysis of mutations in Supplementary Table 3 and COSMIC. Every mutation was assigned a CADD score to assess potential functional impact and deleteriousness (Suppl methods). Variants shaded in light gray were present in only MAP adenomas, variants in white were present only in FAP adenomas and those shaded in dark gray were detected in both FAP and MAP adenomas. An asterisk denotes variants that were identified more than once with a superscript number to designate the number of times the variant was detected. Table 3 . Summary of somatic analyses completed including exome analysis, arrayCGH, APC LOH analysis and targeted sequencing of APC, KRAS, WTX, PTCHD2, ERBB3 and PLCL1. * Analysis completed but no mutation identified.  Mutation identified by exome sequencing.  LOH or CNV detected.  Mutation detected by targeted sequencing. A blank well denotes where a sample was not analysed. Non-independent adenomas are shown in bold, totals reflect the duplication. Gray shading denotes samples that underwent exome sequencing. The table is split to represent the analyses completed on the FAP adenomas in the first section followed by the MAP adenomas in the lower section. The total number of samples screened and mutations detected is given for both the FAP and MAP adenomas individually and then summed across the whole cohort at the end of the table. 
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